bioRxiv Science⌕ Search

Biology subjects

Trzaskalski, N. A.

Publications and source records attributed to Trzaskalski, N. A..

2 recordsLinked to original sources

Thermoneutral housing does not accelerate metabolic dysfunction-associated fatty liver disease in male or female mice fed a Western diet

ObjectiveMetabolic dysfunction-associated fatty liver disease (MAFLD) represents a growing cause of mortality and morbidity and encompasses a spectrum of liver pathologies. Potential therapeutic targets have been identified and are currently being pre-clinically and clinically tested. However, while dozens of preclinical models have been developed to recapitulate various stages of MAFLD, few achieve fibrosis using an experimental design that mimics human pathogenesis. We sought to clarify whether the combination of thermoneutral (TN) housing and consumption of a classical Western diet (WD) would accelerate the onset of MAFLD and progression in male and female mice. MethodsMale and female C57Bl/6J mice were fed a nutrient-matched low-fat control or Western diet (41% Kcal from fat, 43% carbohydrate and 0.2% cholesterol; WD) starting at [~]12 wk of age for a further 16 wk. Mice were divided and housed with littermates at either standard temperature (TS; 22{degrees}C) or thermoneutral conditions (TN; [~]29{degrees}C). Mice underwent tests for glucose tolerance, insulin sensitivity and body composition, as well as intestinal permeability. Following tissue harvest, circulating and liver markers of hepatic disease progression toward steatosis and fibrosis were determined. ResultsWhile male mice housed at TN and fed a WD were significantly heavier than TS -housed control animals, no other differences in body weight or composition were observed. WD-fed females housed under TN conditions had higher circulating LDL-cholesterol; however, there were no other significant differences between TN and TS -housing in circulating or hepatic lipid levels. While WD-fed TN males had higher ALT levels, no other differences in markers of liver injury or disease progression were observed. Moreover, females housed at TN conditions and fed a WD remained significantly protected against the induction of fibrosis compared to male counterparts. Interestingly, sex-specific differences were observed in markers of glucose and insulin tolerance, where TN housing and WD feeding resulted in hyperglycemia and impaired insulin responsiveness in both sexes, but glucose intolerance only in male mice. ConclusionsWhile TN housing has been demonstrated to exacerbate high fat-induced hepatic steatosis and inflammation in male and female mice, coupling TN housing with a WD for 16 wk was not sufficient to augment fatty liver progression in male or female mice. HighlightsO_LIThermoneutral housing and Western diet feeding does not progress to NASH C_LIO_LIFemale mice are not more susceptible to obesity induced fatty liver under these conditions C_LIO_LITemperature and diet had sex-specific effects on glucose tolerance and insulin sensitivity C_LI O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=184 SRC="FIGDIR/small/524609v1_ufig1.gif" ALT="Figure 1"> View larger version (58K): org.highwire.dtl.DTLVardef@9b9c5eorg.highwire.dtl.DTLVardef@36fc5aorg.highwire.dtl.DTLVardef@1f1b244org.highwire.dtl.DTLVardef@eea3df_HPS_FORMAT_FIGEXP M_FIG C_FIG

physiology↗

Myeloid deletion and therapeutic activation of AMP-activated protein kinase (AMPK) do not alter atherosclerosis in male or female mice

ObjectiveThe dysregulation of myeloid-derived cell metabolism can drive atherosclerosis. AMP-activated protein kinase (AMPK) controls various aspects of macrophage dynamics and lipid homeostasis, which are important during atherogenesis. Approach and ResultsWe aimed to clarify the role of myeloid-specific AMPK signaling by using LysM-Cre to drive the deletion of both the 1 and 2 catalytic subunits (MacKO), in male and female mice made acutely atherosclerotic by PCSK9-AAV and Western diet-feeding. After 6 weeks of Western diet feeding, half received daily injection of either the AMPK activator, A-769662 or a vehicle control for a further 6 weeks. After 12 weeks, myeloid cell populations were not different between genotype or sex. Similarly, aortic sinus plaque size, lipid staining and necrotic area were not different in male and female MacKO mice compared to their littermate floxed controls. Moreover, therapeutic intervention with A-769662 had no effect. There were no differences in the amount of circulating total cholesterol or triglyceride, and only minor differences in the levels of inflammatory cytokines between groups. Finally, CD68+ area or markers of autophagy showed no effect of either lacking AMPK signaling or systemic AMPK activation. ConclusionsOur data suggest that while defined roles for each catalytic AMPK subunit have been identified, global deletion of myeloid AMPK signaling does not significantly impact atherosclerosis. Moreover, we show that intervention with the first-generation AMPK activator, A-769662, was not able to stem the progression of atherosclerosis. Highlights- The deletion of both catalytic subunits of AMPK in myeloid cells has no significant effect on the progression of atherosclerosis in either male or female mice - Therapeutic delivery of a first-generation AMPK activator (A-769662) for the last 6 weeks of 12-week study had no beneficial effect in either male or female mice - Studying total AMPK deletion may mask specific effects of each isoform and highlights the need for targeted disruption of AMPK phosphorylation sites via knock-in mutations, rather than the traditional "sledgehammer" knockout approach

biochemistry↗